Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 1, 2008, Pages 312-320

  Cooksley, Helen ^a   Chokshi, Shilpa ^a   Maayan, Yafit ^b   Wedemeyer, Heiner ^c   Andreone, Pietro ^d   Gilson, Richard ^a   Warnes, Thomas ^e   Paganin, Simona ^f   Zoulim, Fabien ^g   Frederick, David ^h   Neumann, Avidan U ^b   Brosgart, Carol L ^h   Naoumov, Nikolai V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BAR ILAN UNIVERSITY   (Israel)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITÉ LYON 1   (France)

^h GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS E ANTIGEN; PLACEBO;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; VIREMIA;

ADENINE; ADULT; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 37849001718     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00467-07     Document Type: Article

References (27)

1. Boni, C., A. Bertoletti, A. Penna, A. Cavalli, M. Pilli, S. Urbani, P. Scognamiglio, R. Boehme, R. Panebianco, F. Fiaccadori, and C. Ferrari. 1998. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Investig. 102:968-975.
2. Boni, C., A. Penna, A. Bertoletti, V. Lamonaca, I. Rapti, G. Missale, M. Pilli, S. Urbani, A. Cavalli, S. Cerioni, R. Panebianco, J. Jenkins, and C. Ferrari. 2003. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J. Hepatol. 39:595-605.
3. Chisari, F. V. 2000. Rous-Whipple award lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am. J. Pathol. 156:1117-1132.
4. Chisari, F. V., and C. Ferrari. 1995. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:29-60.
5. de Franchis, R., A. Hadengue, G. Lau, D. Lavanchy, A. Lok, N. McIntyre, A. Mele, G. Paumgartner, A. Pietrangelo, J. Rodes, W. Rosenberg, D. Valla, and the EASL Jury. 2003. EASL Consensus Conference on Hepatitis B: consensus statement. J. Hepatol. 39(Suppl. 1):S3-S25.
6. Delaney, W. E., S. Locarnini, and T. Shaw. 2001. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir. Chem. Chemother. 12:1-35.
7. Fattovich, G., M. Rugge, L. Brollo, P. Pontisso, F. Noventa, M. Guido, A. Alberti, and G. Realdi. 1986. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 6:167-172.
8. Guidotti, L. G., and F. V. Chisari. 2001. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19:65-91.
9. Lai, C. L., R. N. Chien, N. W. Leung, T. T. Chang, R. Guan, D. I. Tai, K. Y. Ng, P. C. Wu, J. C. Dent, J. Barber, S. L. Stephenson, D. F. Gray, et al. 1998. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:61-68.
10. Lau, G. K., D. Suri, R. Liang, E. I. Rigopoulou, M. G. Thomas, I. Mullerova, A. Nanji, S. T. Vuen, R. Williams, and N. V. Naoumov. 2002. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122:614-624.
11. Le Guerhier, F., A. Thermet, S. Guerret, M. Chevallier, C. Jamard, C. S. Gibbs, C. Trepo, L. Cova, and F. Zoulim. 2003. Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. J. Hepatol. 38:328-334.
12. Lok, A. S., and B. J. McMahon. 2001. AASLD practice guidelines: chronic hepatitis B. Hepatology 34:1225-1241.
13. Marcellin, P., T. T. Chang, S. G. Lim, M. J. Tong, W. Sievert, M. L. Shiffman, L. Jeffers, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348:808-816.
14. Marinos, G., N. V. Naoumov, and R. Williams. 1996. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 24:991-995.
15. Marusawa, H., S. Uemoto, M. Hijikata, Y. Ueda, K. Tanaka, K. Shimotohno, and T. Chiba. 2000. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B'core antigen. Hepatology 31:488-495.
16. Maruyama, T., S. Iino, K. Koike, K. Yasuda, and D. R. Milich. 1993. Serology of acute exacerbation in chronic hepatitis B virus infection. Gastroenterology 105:1141-1151.
17. Menne, S., C. A. Roneker, B. E. Korba, J. L. Gerin, B. C. Tennant, and P. J. Cote. 2002. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J. Virol. 76:5305-5314.
18. Milich, D. R., M. K. Chen, J. L. Hughes, and J. E. Jones. 1998. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J. Immunol. 160:2013-2021.
19. Milich, D. R., and A. McLachlan. 1986. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 234:1398-1401.
20. Niederau, C., T. Heintges, S. Lange, G. Goldmann, C. M. Niederau, L. Mohr, and D. Haussinger. 1996. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 334:1422-1427.
21. Penna, A., M. Artini, A. Cavalli, M. Levrero, A. Bertoletti, M. Pilli, F. V. Chisari, B. Rehermann, P. G. Del, F. Fiaccadori, and C. Ferrari. 1996. Long-lasting memory T cell responses following self-limited acute hepatitis B. J. Clin. Investig. 98:1185-1194.
22. Rehermann, B., C. Ferrari, C. Pasquinelli, and F. V. Chisari. 1996. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2:1104-1108.
23. Rehermann, B., and M. Nascimbeni. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5:215-229.
24. Rigopoulou, E. I., D. Suri, S. Chokshi, I. Mullerova, S. Rice, R. S. Tedder, R. Williams, and N. V. Naoumov. 2005. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 42:1028-1036.
25. Suri, D., R. Schilling, A. R. Lopes, I. Mullerova, G. Colucci, R. Williams, and N. V. Naoumov. 2001. Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. J. Hepatol. 35:790-797.
26. Tsiang, M., J. F. Rooney, J. J. Toole, and C. S. Gibbs. 1999. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 29:1863-1869.
27. Wong, D. K., A. M. Cheung, K. O'Rourke, C. D. Naylor, A. S. Detsky, and J. Heathcote. 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 119:312-323.